The role of cardiovascular pharmacology and therapeutics extends far beyond traditional drug regimens, encompassing groundbreaking treatments that address the intricate mechanisms of heart diseases. Recent developments include RNA-based therapies and regenerative drugs designed to repair cardiac tissue at a molecular level. Researchers are also investigating the role of anti-inflammatory agents in reducing atherosclerosis progression. Clinical trials for novel anticoagulants and lipid-lowering medications continue to refine strategies for preventing thrombotic events and improving long-term patient health. This dynamic field integrates pharmacological advances with patient-specific approaches to enhance both the efficacy and safety of cardiovascular care.
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : CARDIAC TROPONIN AND HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH DIALYSIS VINTAGE AND CARDIOVASCULAR COMORBIDITY
Sofra Maria, Aretaieion University Hospital, Greece
Title : Finite-Element and Electromagnetic Cardio-Vascular Simulation for Drug Testing, Monitoring, and Safety Projection Using Bansal B–Bio Framework
Abhishek Bansal, New Era Consultancy Services, India
Title : Lipid and High-Density Lipoprotein (HDL) Subfraction Changes in Premenopausal and Postmenopausal Women with Breast Cancer Receiving Hormonal Therapy
Sofra Maria, Aretaieion University Hospital, Greece